SRER (n=25) | ER + RFA (n=22) | p Value | |
Male:female | 21:4 | 19:3 | 1.00 |
Median age (years) (range) | 68 (45–88) | 69 (55–73) | 0.97 |
Median BO (cm) | C2, M4 | C2, M4 | C 0.99 |
(IQR C1–3; M2-5) | (IQR C1-3; M2–5) | M 0.89 | |
Visible lesion prior to treatment | 17/25 (68%) | 18/22 (82%) | 0.33 |
Lesion type prior to treatment (Paris classification)23 | 0-IIa: 9 | 0-IIa: 6 | – |
IIa-c: 4/0-IIc: 1 | 0-IIa-c: 9 | ||
IIa+I: 2/0–Is: 1 | 0-IIa+I: 3 | ||
Staging ER prior to randomisation | 10 | 12* | 0.39 |
ER after randomisation | 15 | 6* | 0.04 |
Worst diagnosis histology of biopsies or ER specimens | 13 EC/12 HGD | 15 EC/7 HGD | 0.37 |
↵* Of the 22 patients in the RFA arm, 12 underwent a diagnostic ER for staging purposes and were then randomised to the RFA arm, 6 other patients with visible lesions underwent ER after they were randomised to RFA. Four patients in the RFA arm did not show visible abnormalities and underwent RFA monotherapy.
BO, Barrett's oesophagus; C, length of circumferential BO; EC, early cancer; ER, endoscopic resection; HGD, high-grade dysplasia; M, maximal BO length; RFA, radiofrequency ablation; SRER, stepwise radical endoscopic resection.